Telemedicine Growth Strategies: Insights from the WHO European Region

By João L. Carapinha

June 12, 2025

The recently published WHO policy brief, Scaling Up Telemedicine in the WHO European Region, outlines the rapid adoption of telemedicine growth strategies during the COVID-19 pandemic. It identifies systemic barriers to its long-term integration into routine care. Key findings emphasize that 78% of Member States now include telehealth in national strategies. Post-pandemic integration remains uneven due to regulatory inconsistencies, infrastructure gaps, and reimbursement challenges. The report advocates for value-based financing, and standardized clinical guidelines to ensure telemedicine enhances universal health coverage without exacerbating disparities.

Insights into Telemedicine Trends

The pandemic accelerated telemedicine adoption. Teleradiology, telepsychiatry, and general telemedicine became the most utilized services. However, only 53% of countries have defined reimbursement models. Temporary funding measures during COVID-19 risk discontinuation. Clinician acceptance varies, with European family physicians estimating that 20% of future consultations will be remote. Many still prefer in-person care. Structural barriers persist, such as inadequate digital infrastructure in rural areas and interoperability gaps in electronic health records. Telemedicine has demonstrated clinical efficacy in chronic disease management. It reduces hospital readmissions and improves access for marginalized populations when equity-by-design principles are applied.

Economic Implications and Policy Recommendations

The WHO’s findings align with broader trends. Telemedicine can reduce costs for acute care visit, and lower hospitalization rates when paired with remote monitoring. There are funding and infrastructure barriers that require interoperability strategies to align with current clinical and operational practices.

The policy brief calls for value-based reimbursement. These suggest shifting from fee-for-service models to capitation or bundled payments. For example, Germany’s DiGA framework ties reimbursement to demonstrated clinical benefits. France’s PECAN mechanism allows transitional pricing for innovative solutions. Such models incentivize quality but require robust cost-effectiveness data. Health technology assessment (HTA) agencies play critical roles in evaluating digital therapeutics. Fragmented EU regulations complicate cross-border scalability.

Only 33% of Member States have digital inclusion strategies. This risks exclusion for elderly, rural, and low-literacy populations. Telehealth reimbursement parity with in-person care can improve access, as would targeted training for providers to integrate telehealth practices in their daily operations.

Strategies for Sustainable Integration

Sustainable telemedicine integration demands multi-stakeholder collaboration. Policymakers must prioritize interoperable digital infrastructure, leveraging EU-wide standards for data sharing and cybersecurity. Permanent reimbursement frameworks should be informed by value-based pricing. Protocols are essential, including multilingual platforms and low-bandwidth solutions for rural areas. Workforce training programs can address digital literacy gaps, to enable national telehealth scaling.

Failure to address these dimensions risks entrenching telemedicine as a fragmented adjunct rather than a transformative tool. The future of telehealth hinges on aligning clinical, economic, and social imperatives to ensure high-quality care across the European Region. For additional insights, see the comprehensive analysis provided by the World Health Organization here.

Reference url

Recent Posts

Impact of Generic Liraglutide Launch on Weight Management and Health Economics

By João L. Carapinha

September 3, 2025

Teva’s recent announcement of the U.S. Food and Drug Administration (FDA) approval and the generic liraglutide launch marks a significant development in the weight-loss therapeutics market. The introduction of the first generic version of Saxenda (liraglutide) injection highlights both a critical...
Collaboration Cardiac Surgery: Boosting Surgical Volumes Through Multidisciplinary Teams

By João L. Carapinha

September 1, 2025

Cardiovascular Business recently examines how closer collaboration cardiac surgery between interventional cardiologists and cardiac surgeons can increase patient referrals for surgical interventions. This is especially important as less-invasive procedures like transcatheter interventions grow in...
Mounjaro Price Increase UK: Impacts on Access and Health Economics
Eli Lilly is raising Mounjaro's UK price by 170% on September 1, 2025. The highest dose will jump from £122 to £330 monthly. But the company has negotiated discounts with pharmacies. This will lower the effective price to £247.50. This hike aims to align international pricing as it responds to pr...